

Paul R Harnett

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/967089/publications.pdf>

Version: 2024-02-01

100
papers

4,568
citations

136950

32
h-index

106344

65
g-index

103
all docs

103
docs citations

103
times ranked

7899
citing authors

#	ARTICLE	IF	CITATIONS
1	Whole-genome characterization of chemoresistant ovarian cancer. <i>Nature</i> , 2015, 521, 489-494.	27.8	1,206
2	Integrated Genome-Wide DNA Copy Number and Expression Analysis Identifies Distinct Mechanisms of Primary Chemoresistance in Ovarian Carcinomas. <i>Clinical Cancer Research</i> , 2009, 15, 1417-1427.	7.0	266
3	Dose-Response Association of CD8 ⁺ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. <i>JAMA Oncology</i> , 2017, 3, e173290.	7.1	260
4	Loss of alleles from the distal short arm of chromosome 1 occurs late in melanoma tumor progression.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1989, 86, 4614-4618.	7.1	202
5	Two-dimensional myocardial strain imaging detects changes in left ventricular systolic function immediately after anthracycline chemotherapy. <i>European Journal of Echocardiography</i> , 2011, 12, 945-952.	2.3	135
6	A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer. <i>Annals of Oncology</i> , 1998, 9, 1343-1345.	1.2	121
7	ABCA Transporter Gene Expression and Poor Outcome in Epithelial Ovarian Cancer. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	6.3	107
8	LRP1B Deletion in High-Grade Serous Ovarian Cancers Is Associated with Acquired Chemotherapy Resistance to Liposomal Doxorubicin. <i>Cancer Research</i> , 2012, 72, 4060-4073.	0.9	100
9	Genomic Classification of Serous Ovarian Cancer with Adjacent Borderline Differentiates RAS Pathway and TP53-Mutant Tumors and Identifies NRAS as an Oncogenic Driver. <i>Clinical Cancer Research</i> , 2014, 20, 6618-6630.	7.0	96
10	ABCB1 (MDR 1) Polymorphisms and Progression-Free Survival among Women with Ovarian Cancer following Paclitaxel/Carboplatin Chemotherapy. <i>Clinical Cancer Research</i> , 2008, 14, 5594-5601.	7.0	90
11	Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial. <i>Lancet Oncology</i> , The, 2019, 20, 1306-1315.	10.7	87
12	Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss Are Associated with Exceptional Survival in High-Grade Serous Ovarian Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 569-580.	7.0	79
13	Tumor protein D52 (TPD52) is overexpressed and a gene amplification target in ovarian cancer. <i>International Journal of Cancer</i> , 2005, 117, 1049-1054.	5.1	78
14	Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study. <i>Journal of Pathology: Clinical Research</i> , 2018, 4, 250-261.	3.0	70
15	New therapies for ovarian cancer: Cytotoxics and molecularly targeted agents. <i>Critical Reviews in Oncology/Hematology</i> , 2008, 67, 103-112.	4.4	69
16	Anthracyclines induce early changes in left ventricular systolic and diastolic function: A single centre study. <i>PLoS ONE</i> , 2017, 12, e0175544.	2.5	64
17	Altered left ventricular longitudinal diastolic function correlates with reduced systolic function immediately after anthracycline chemotherapy. <i>European Heart Journal Cardiovascular Imaging</i> , 2013, 14, 228-234.	1.2	61
18	MRP2 (ABCC2) and cisplatin sensitivity in hepatocytes and human ovarian carcinoma. <i>Gynecologic Oncology</i> , 2006, 100, 239-246.	1.4	58

#	ARTICLE	IF	CITATIONS
19	<i>EIF1AX</i> and <i>NRAS</i> Mutations Co-occur and Cooperate in Low-Grade Serous Ovarian Carcinomas. <i>Cancer Research</i> , 2017, 77, 4268-4278.	0.9	56
20	Left ventricular systolic function in HER2/neu negative breast cancer patients treated with anthracycline chemotherapy: A comparative analysis of left ventricular ejection fraction and myocardial strain imaging over 12 months. <i>European Journal of Cancer</i> , 2013, 49, 3396-3403.	2.8	54
21	A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases. <i>Modern Pathology</i> , 2019, 32, 1834-1846.	5.5	54
22	Loss of allelic heterozygosity on distal chromosome 1p in Merkel cell carcinoma. <i>Cancer Genetics and Cytogenetics</i> , 1991, 54, 109-113.	1.0	52
23	Expression of Progesterone Receptor A and B Isoforms in Low-grade Endometrial Stromal Sarcoma. <i>International Journal of Gynecological Pathology</i> , 2004, 23, 138-144.	1.4	50
24	Home or Hospital? An Evaluation of the Costs, Preferences, and Outcomes of Domiciliary Chemotherapy. <i>International Journal of Health Services</i> , 2000, 30, 557-579.	2.5	49
25	The Role of KRAS rs61764370 in Invasive Epithelial Ovarian Cancer: Implications for Clinical Testing. <i>Clinical Cancer Research</i> , 2011, 17, 3742-3750.	7.0	47
26	Improved ovarian cancer EMT-CTC isolation by immunomagnetic targeting of epithelial EpCAM and mesenchymal N-cadherin. <i>Journal of Circulating Biomarkers</i> , 2018, 7, 184945441878261.	1.3	47
27	A comparison of two Quality-of-Life Questionnaires for cancer clinical trials: The Functional Living Index-Cancer (FLIC) and the Quality of Life Questionnaire Core module (QLQ-C30). <i>Journal of Clinical Epidemiology</i> , 1996, 49, 21-29.	5.0	44
28	Carboplatin and paclitaxel interact antagonistically in a megakaryoblast cell line - a potential mechanism for paclitaxel-mediated sparing of carboplatin-induced thrombocytopenia. <i>Cancer Chemotherapy and Pharmacology</i> , 2001, 48, 229-234.	2.3	38
29	Inhibition of ANKRD1 sensitizes human ovarian cancer cells to endoplasmic reticulum stress-induced apoptosis. <i>Oncogene</i> , 2015, 34, 485-495.	5.9	38
30	A cost-utility approach to the use of 5-fluorouracil and levamisole as adjuvant chemotherapy for Dukes' C colonic carcinoma. <i>Medical Journal of Australia</i> , 1993, 158, 319-322.	1.7	37
31	Comparison of Expression Profiles in Ovarian Epithelium In Vivo and Ovarian Cancer Identifies Novel Candidate Genes Involved in Disease Pathogenesis. <i>PLoS ONE</i> , 2011, 6, e17617.	2.5	36
32	A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study. <i>Breast Cancer Research and Treatment</i> , 2017, 161, 63-72.	2.5	35
33	Carboplatin desensitization. <i>Annals of Allergy, Asthma and Immunology</i> , 2004, 93, 137-141.	1.0	33
34	Ankyrin Repeat Domain 1, <i>ANKRD1</i> , a Novel Determinant of Cisplatin Sensitivity Expressed in Ovarian Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 6924-6932.	7.0	33
35	Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance. <i>Gynecologic Oncology</i> , 2018, 150, 239-246.	1.4	32
36	Multidisciplinary teams and ICT: a qualitative study exploring the use of technology and its impact on multidisciplinary team meetings. <i>BMC Health Services Research</i> , 2018, 18, 444.	2.2	30

#	ARTICLE	IF	CITATIONS
37	Germline polymorphisms in an enhancer of <i>PSIP1</i> are associated with progression-free survival in epithelial ovarian cancer. <i>Oncotarget</i> , 2016, 7, 6353-6368.	1.8	29
38	Demonstration of somatic rearrangements and genomic heterogeneity in human ovarian cancer by DNA fingerprinting. <i>British Journal of Cancer</i> , 1990, 62, 23-27.	6.4	26
39	Scientists and clinicians test their metalâ€“back to the future with platinum compounds. <i>Lancet Oncology</i> , The, 2002, 3, 312-318.	10.7	26
40	Impact of baseline and nadir neutrophil index in non-small cell lung cancer and ovarian cancer patients: Assessment of chemotherapy for resolution of unfavourable neutrophilia. <i>Journal of Translational Medicine</i> , 2013, 11, 189.	4.4	25
41	Weekly AUC2 carboplatin in acquired platinum-resistant ovarian cancer with or without oral phenoxodiol, a sensitizer of platinum cytotoxicity: the phase III OVATURE multicenter randomized study. <i>Annals of Oncology</i> , 2014, 25, 160-165.	1.2	25
42	Repair of cisplatin-DNA adducts by protein extracts from human ovarian carcinoma. <i>International Journal of Cancer</i> , 1994, 59, 388-393.	5.1	24
43	Paclitaxel sensitivity in relation to ABCB1 expression, efflux and single nucleotide polymorphisms in ovarian cancer. <i>Scientific Reports</i> , 2014, 4, 4669.	3.3	24
44	A phase II trial of capecitabine in heavily pre-treated platinum-resistant ovarian cancer. <i>Gynecologic Oncology</i> , 2004, 93, 417-421.	1.4	23
45	New therapeutic opportunities for women with low-grade serous ovarian cancer. <i>Endocrine-Related Cancer</i> , 2022, 29, R1-R16.	3.1	23
46	MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. <i>Mayo Clinic Proceedings</i> , 2018, 93, 307-320.	3.0	22
47	Aminoglutethimide in Advanced Prostatic Carcinoma. <i>British Journal of Urology</i> , 1987, 59, 323-327.	0.1	21
48	Successful carboplatin desensitization by using omalizumab and paradoxical diminution of total IgE levels. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2014, 2, 105-106.	3.8	19
49	<i>BRAF</i> Mutations in Low-Grade Serous Ovarian Cancer and Response to BRAF Inhibition. <i>JCO Precision Oncology</i> , 2018, 2, 1-14.	3.0	19
50	Attitudes of health professionals to using routinely collected clinical data for performance feedback and personalised professional development. <i>Medical Journal of Australia</i> , 2019, 210, S17-S21.	1.7	19
51	Embedding continuous quality improvement processes in multidisciplinary teams in cancer care: exploring the boundaries between quality and implementation science. <i>Australian Health Review</i> , 2017, 41, 291.	1.1	18
52	Phase II study of gemcitabine and oxaliplatin in patients with recurrent ovarian cancer: an Australian and New Zealand Gynaecological Oncology Group study. <i>International Journal of Gynecological Cancer</i> , 2007, 17, 359-366.	2.5	17
53	Serous ovarian and primary peritoneal cancers: A comparative analysis of clinico-pathological features, molecular subtypes and treatment outcome. <i>Gynecologic Oncology</i> , 2016, 142, 458-464.	1.4	17
54	A randomised crossover trial of chemotherapy in the home: patient preferences and cost analysis. <i>Medical Journal of Australia</i> , 2001, 174, 312-312.	1.7	16

#	ARTICLE	IF	CITATIONS
55	Validated biomarker assays confirm that <scp>ARID1A</scp> loss is confounded with <scp>MMR</scp> deficiency, <scp>CD8⁺ TIL</scp> infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomas. <i>Journal of Pathology</i> , 2022, 256, 388-401.	4.5	15
56	Developing an Intranet-Based Lymphedema Dashboard for Breast Cancer Multidisciplinary Teams: Design Research Study. <i>Journal of Medical Internet Research</i> , 2020, 22, e13188.	4.3	13
57	"But Doctor, What Have I Got to Lose . . . ?". <i>Journal of Clinical Oncology</i> , 2001, 19, 3294-3296.	1.6	12
58	Cancergazing? CA125 and post-treatment surveillance in advanced ovarian cancer. <i>Social Science and Medicine</i> , 2010, 71, 1548-1556.	3.8	12
59	Patterns and trends in the incidence of paediatric and adult germ cell tumours in Australia, 1982-2011. <i>Cancer Epidemiology</i> , 2016, 43, 15-21.	1.9	12
60	A phase 1b study of the anti-PD-1 monoclonal antibody BGB-A317 (A317) in combination with the PARP inhibitor BGB-290 (290) in advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2018, 36, 48-48.	1.6	12
61	Phase II study of carboplatin followed by sequential gemcitabine and paclitaxel as first-line treatment for advanced ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2007, 17, 350-358.	2.5	11
62	A mixed methods approach to developing and evaluating oncology trainee education around minimization of adverse events and improved patient quality and safety. <i>BMC Medical Education</i> , 2016, 16, 91.	2.4	11
63	A tool to improve the performance of multidisciplinary teams in cancer care. <i>BMJ Open Quality</i> , 2019, 8, e000435.	1.1	11
64	Integrated Multimodality Therapy for Embryonal Rhabdomyosarcoma of the Lower Genital Tract in Postpubertal Females. <i>Gynecologic Oncology</i> , 1998, 70, 141-146.	1.4	10
65	Elevated germ cell markers in carcinoma of uncertain primary site do not predict response to platinum based chemotherapy. <i>European Journal of Cancer</i> , 1996, 32, 2357-2359.	2.8	9
66	PRIMARY PERITONEAL CARCINOMA: A TREATABLE SUBSET OF PATIENTS WITH ADENOCARCINOMA OF UNKNOWN PRIMARY. <i>ANZ Journal of Surgery</i> , 1996, 66, 124-125.	0.7	8
67	Inflammatory breast cancer: enhanced local control with hyperfractionated radiotherapy and incisional vincristine, ifosfamide and epirubicin. <i>Australian and New Zealand Journal of Medicine</i> , 1998, 28, 400-402.	0.5	8
68	Adenocarcinoma of the Duodenum With Liver Metastases. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1996, 19, 305-306.	1.3	8
69	"But Doctor, What Have I Got to Lose . . . ?". <i>Journal of Clinical Oncology</i> , 2003, 21, 27s-29.	1.6	8
70	MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 480, 855-871.	2.8	8
71	Recurrent ovarian cancer: Treatment with pegylated liposomal doxorubicin; a Westmead Cancer Care Centre experience. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2010, 6, 66-73.	1.1	6
72	Drug resistance in clinical practice: Patterns of treatment failure in patients receiving systemic therapy for advanced breast cancer. <i>European Journal of Cancer & Clinical Oncology</i> , 1987, 23, 1601-1605.	0.7	5

#	ARTICLE	IF	CITATIONS
73	Orbital Metastasis from Prostatic Carcinoma. <i>British Journal of Urology</i> , 1987, 59, 591-592.	0.1	5
74	Heterogeneous repair of platinum-DNA adducts by protein extracts from mammalian tissues. <i>Biochemical Pharmacology</i> , 1994, 48, 1662-1665.	4.4	5
75	Continuous infusion of vincristine, ifosfamide and epirubicin over 6 weeks in treatment-resistant advanced breast cancer. <i>European Journal of Cancer</i> , 1995, 31, 1773-1777.	2.8	5
76	An Online Learning Module to Increase Self-Efficacy and Involvement in Care for Patients With Advanced Lung Cancer: Research Protocol. <i>JMIR Research Protocols</i> , 2016, 5, e147.	1.0	5
77	Mechanisms determining sensitivity to cisplatin in three mutant Chinese hamster ovary cell lines. <i>Mutation Research DNA Repair</i> , 1998, 407, 243-252.	3.7	4
78	Choriocarcinoma of the lung masquerading as a persisting pregnancy of unknown location (<sc>PUL</sc>). <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2012, 52, 211-212.	1.0	3
79	The perils of a vanishing cohort: a study of social comparisons by women with advanced ovarian cancer. <i>Psycho-Oncology</i> , 2012, 21, 382-391.	2.3	3
80	Retrospective imaging audit and cost analysis of medical oncology inpatients admitted to <sc>W</sc>estmead <sc>H</sc>ospital. <i>Internal Medicine Journal</i> , 2014, 44, 1235-1239.	0.8	3
81	Genome-wide association study of paclitaxel and carboplatin disposition in women with epithelial ovarian cancer. <i>Scientific Reports</i> , 2018, 8, 1508.	3.3	3
82	Improving Cancer MDT performance in Western Sydney â€“ three yearsâ€™ experience. <i>BMC Health Services Research</i> , 2021, 21, 203.	2.2	3
83	Maximum Tolerated Dose and Anti-Tumor Activity of Intraperitoneal Cantrixil (TRX-E-002-1) in Patients with Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer: Phase I Study Results. <i>Cancers</i> , 2021, 13, 3196.	3.7	3
84	Developing a maturity model for cancer multidisciplinary teams. <i>International Journal of Medical Informatics</i> , 2021, 156, 104610.	3.3	3
85	Cisplatin plus VP16-213 in advanced ovarian carcinoma. <i>Gynecologic Oncology</i> , 1988, 30, 159-162.	1.4	2
86	Adjuvant chemotherapy for node-positive breast cancer: a retrospective comparison of two different regimens of cyclophosphamide, methotrexate and 5-fluorouracil. <i>Breast</i> , 1999, 8, 28-34.	2.2	2
87	CARBOPLATIN DESENSITIZATION. <i>Annals of Allergy, Asthma and Immunology</i> , 2007, 99, 468-469.	1.0	2
88	Transducin-Like Enhancer of Split 3 (TLE3) Expression Is Associated with Taxane Sensitivity in Nonserous Ovarian Carcinoma in a Three-Cohort Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018, 27, 680-688.	2.5	2
89	Managing quality in cancer services: why improvement isn't easy. <i>Australian Health Review</i> , 2005, 29, 406.	1.1	2
90	Vertebral osteomyelitis in advanced breast cancer. <i>Australian and New Zealand Journal of Medicine</i> , 1993, 23, 406-406.	0.5	1

#	ARTICLE	IF	CITATIONS
91	NT-proBNP Changes in Patients with Ascites during Large Volume Paracentesis. ISRN Hepatology, 2013, 2013, 1-7.	0.9	1
92	Persisting elevation of alphafetoprotein after chemotherapy for germ cell tumour" not always due to viable malignancy?. European Journal of Cancer, 1995, 31, 1722.	2.8	0
93	I now wear a white coat. Medical Journal of Australia, 2001, 175, 228-228.	1.7	0
94	All pains are equal, but some seem more urgent than others. Lancet, The, 2012, 380, 28.	13.7	0
95	Beyond evidence: reappraising use of CA125 as posttherapy surveillance for ovarian cancer. Medical Journal of Australia, 2012, 196, 440-441.	1.7	0
96	Carboplatin allergy and IgE regulation. Pathology, 2016, 48, S48.	0.6	0
97	Our Faustian pact with the digital world. Lancet Oncology, The, 2017, 18, 171-172.	10.7	0
98	Epithelial ovarian cancer: Genomic landscape and evolving precision treatment. , 2021, , 1-23.		0
99	A costutility approach to the use of 5-fluorouracil and levamisole as adjuvant chemotherapy for Dukes' C colonic carcinoma. Medical Journal of Australia, 1993, 158, 866-866.	1.7	0
100	Genome-wide association study for identification of candidate SNPs associated with carboplatin and paclitaxel clearance in ovarian cancer patients.. Journal of Clinical Oncology, 2014, 32, 5563-5563.	1.6	0